Cellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments—Biologics License Application (BLA) 125827, From Replimune, Inc. for Vusolimogene Oderparepvec
FDA_FRDOC_0001-14338Notice
Comments
130
Awaiting comments
Deadline
Closed on Jul 30, 2026
Closed Jul 30, 2026
Net supportiSupport minus oppose · campaigns included
—
Document
Details
The document's own metadata, straight from the source system.
- Title
- Cellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments—Biologics License Application (BLA) 125827, From Replimune, Inc. for Vusolimogene Oderparepvec
- Posted
- Jul 8, 2026
- Comment period
- Jul 8, 2026 – Jul 30, 2026
- FR Doc
- 2026-13810
Analysis
Overview
What the public is saying — stance, who's commenting, and the issues they raise.
Include campaigns
Analyzed 0 of 130 comments
0%· analysis in progress
Stance breakdown
—
Net support
Not yet analyzed130
Who commented
Breakdown by commenter type.
Not yet analyzed
130
Issues raised
The docket's canonical issues. Select one to browse its comments.
Issues are identified as comment analysis progresses — nothing tagged on this document yet.
Comments
Explorer
Every mirrored comment — filter by stance, campaign, or issue.
Filter:
No comments match.